TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07751991: A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML

Sponsor: Charm Therapeutics · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 40 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$848,232

Rescue Site Savings

+$565,488

Unlock Full NCT07751991 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07751991 Rescue Dossier →